← All trials
NCT05327647
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 23, 2022
- Primary completion
- Jul 1, 2024
- Completion date
- Dec 31, 2026
- First posted
- Apr 14, 2022
- Last posted
- Jul 15, 2022
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Laval UniversityLead sponsor
- Canadian Institutes of Health Research (CIHR)Collaborator
- Laval UniversityStudy chair
- McGill UniversityOverall official - principal investigator
- McGill UniversityOfficial
- Laval UniversityOfficial
- University of TorontoOfficial
- The Cancer Research SocietyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.